Excellent Response to Gefitinib in a Patient with Erlotinib Refractory, Exon 21, L858r Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(03): 421-423
DOI: 10.4103/ijmpo.ijmpo_22_17

Letters to Editor

Ajay Gupta

Department of Medical Oncology, Vancouver General Hospital, All India Institute of Medical Sciences, New Delhi, India

References
1 Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42
2 Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11
3 Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT. et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006; 25: 1205-15
4 Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-27
5 Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC. et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges – Role of EGFR mutation. Nat Clin Pract Oncol 2006; 3: 50-7